AVITA Medical (NASDAQ: RCEL, ASX: AVH) has exciting news: the FDA has approved their RECELL GO® mini, a new addition to their RECELL GO system, designed specifically for treating smaller wounds up to 480 square centimeters. This approval is a big deal because it fills a crucial gap in the treatment of smaller wounds, which are common in trauma and burn centers.
The RECELL GO mini uses the same multi-use device as the standard RECELL GO but with a modified cartridge that’s optimized for smaller skin samples. This means less waste and more resource efficiency—all while making it easier for clinicians to use this advanced treatment for smaller wounds that they might not have treated with the larger RECELL GO system.
Jim Corbett, CEO of AVITA Medical, emphasized the significance of this approval:
“By introducing a treatment option specifically for smaller wounds, we are expanding the accessibility of RECELL to a wider range of patients. This addition will drive greater adoption across trauma centers, where smaller wounds are common, and support our broader growth strategy.”
What’s Next for RECELL GO Mini?
This launch is expected to boost adoption across trauma and burn centers, with rollout planned for Q1 2025. It’s a smart move by AVITA Medical, as they continue to build on the success of their RECELL platform and address an important need in the wound care market.
The RECELL GO mini is the latest step in AVITA Medical’s plan to expand its impact on patient care and support broader growth in the wound care sector.
